The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Elevidys, after three patients died from liver failure after taking it or a similar treatment.
Source link
Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys
Related Posts
Fact of the Week – 10/6/2025
#Factoftheweek AI (artificial intelligence) spending is about to hit $1.5 trillion in 2025, and this is just the beginning. Gartner projects global AI investment will soar past $2 trillion in…
Success Stories: Tech Reshapes Research
Universities are increasingly innovating how research support is delivered as demands for advanced information technology grow. As one example, Texas A&M AgriLife is piloting a new model for tech access…
